Valeant Pharma (VRX) Announces Key Management Changes; Includes New Business Strategy SVP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Valeant Pharmaceuticals Announces Changes To Executive Management Team
August 8, 2016 8:00 AM EDTChristina Ackermann Named Executive Vice President and General Counsel
Scott Hirsch Joins Valeant as Senior Vice President, Business Strategy and Communications
Senior Leaders Take on Expanded Roles; Executive Committee Realigned to Include Leaders from Key Business and Functional Areas
LAVAL, Quebec, Aug. 8, 2016 /PRNewswire/ --Â Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced a series of leadership and organizational changes.
Christina Ackermann Named Executive Vice President and General Counsel
Effective August 8, 2016, Christina Ackermann has been named... More
